Research Analysts Set Expectations for RVMD FY2029 Earnings

Posted by Stanley Muller on Nov 6th, 2026

Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) – Analysts at Brookline Capital Markets reduced their FY2029 earnings per share (EPS) estimates for Revolution Medicines in a research report issued to clients and investors on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $8.49 per share for the year, down from their previous forecast of $8.94. Brookline Capital Markets has a “Buy” rating and a $318.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.94) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ FY2030 earnings at $17.41 EPS.

A number of other brokerages also recently issued reports on RVMD. The Goldman Sachs Group began coverage on shares of Revolution Medicines in a research report on Thursday, September 24th. They issued a “buy” rating and a $267.00 price objective on the stock. Sanford C. Bernstein increased their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Royal Bank Of Canada lifted their price target on shares of Revolution Medicines from $260.00 to $321.00 and gave the stock an “outperform” rating in a report on Thursday. Piper Sandler upped their price target on Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, UBS Group increased their price objective on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a report on Friday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $259.65.

Check Out Our Latest Stock Analysis on RVMD

Revolution Medicines Stock Down 11.0%

NASDAQ:RVMD opened at $177.65 on Friday. Revolution Medicines has a fifty-two week low of $58.91 and a fifty-two week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The company’s 50-day simple moving average is $197.46 and its 200-day simple moving average is $157.18.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to the consensus estimate of $25.58 million. During the same quarter in the prior year, the firm posted ($1.61) earnings per share.

Insider Activity

In related news, insider Stephen Kelsey sold 92,531 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $202.36, for a total value of $18,724,573.16. Following the completion of the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at $59,064,027.36. This trade represents a 24.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Goldsmith sold 80,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the transaction, the insider directly owned 267,330 shares of the company’s stock, valued at $55,925,436. The trade was a 23.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 290,991 shares of company stock valued at $59,422,765. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new stake in shares of Revolution Medicines during the third quarter valued at $304,000. Fifth Third Bancorp increased its position in shares of Revolution Medicines by 56.2% in the 3rd quarter. Fifth Third Bancorp now owns 4,100 shares of the company’s stock valued at $842,000 after acquiring an additional 1,475 shares during the period. Maryland State Retirement & Pension System raised its stake in Revolution Medicines by 14.6% in the 3rd quarter. Maryland State Retirement & Pension System now owns 11,608 shares of the company’s stock worth $2,383,000 after acquiring an additional 1,478 shares during the last quarter. Ritholtz Wealth Management raised its stake in Revolution Medicines by 10.6% in the 3rd quarter. Ritholtz Wealth Management now owns 4,480 shares of the company’s stock worth $920,000 after acquiring an additional 429 shares during the last quarter. Finally, Lido Advisors LLC purchased a new position in Revolution Medicines in the 3rd quarter worth $1,687,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

Positive Sentiment: Third-quarter revenue reached $197.6 million, far above the $25.58 million consensus estimate. Nearly all of it came from RASONQUE during its first five weeks on the U.S. market; reports cited treatment of more than 5,000 patients. The quarterly loss of $1.90 per share was also narrower than the expected $2.35, though wider than a year earlier. Zacks report on Q3 sales and RASONQUE uptake
Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for daraxonrasib (RASONQUE) in the EU, adding a potential international growth opportunity. Company Q3 results and corporate update
Positive Sentiment: Several firms raised their targets and maintained bullish ratings. RBC increased its target to $321 from $260 with an Outperform rating; TD Cowen raised its target to $270, and Guggenheim to $298, both with Buy ratings. RBC price-target report
Negative Sentiment: Brookline Capital Markets lowered its FY2029 and FY2030 EPS forecasts to $8.49 and $17.41, respectively, from $8.94 and $18.15. It nevertheless kept its Buy rating and $318 price target.

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.